No products in the cart.
Pre-made Rontalizumab benchmark antibody ( Whole mAb, anti-IFNA1 therapeutic antibody, Anti-IFL/IFN3/leIF DD Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-494
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rontalizumab is a humanized monoclonal antibody being developed by Genentech. As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.¡¢
| Products Name (INN Index) | Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody |
|---|---|
| INN Name | Rontalizumab |
| Target | IFNA1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Chugai Pharmaceutical,Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNA1 |
| Package |
Previous slide
Next slide
